Vertex Pharma (VRTX) Misses Q4 EPS by 8c, Revenues Beat; Provides FY21 Product Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
February 1, 2021 4:01 PM EST-Full-year 2020 GAAP product revenues of $6.20 billion-
-Full-year 2020 non-GAAP product revenues of $6.20 billion, a 55% increase compared to full-year 2019-
-Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2020 and provided full-year 2021 financial guidance.
"Our achievements in 2020 were marked by a significant increase in the number of people treated with the triple... More
